In March, about 15 million Johnson & Johnson COVID-19 vaccine doses were ruined at a Baltimore Emergent BioSolutions plant. The doses were ruined after employees mixed up ingredients for Johnson & Johnson’s and AstraZeneca’s COVID-19 vaccines, as AstraZeneca had also contracted with Emergent to make its vaccines there. HHS ordered Emergent to stop making the AstraZeneca vaccine at that plant to avoid further mistakes.
Emergent promised to implement several corrective actions during May and June, all of which need to be achieved before the site can go back to producing COVID-19 vaccines.
Once the plant is authorized to continue manufacturing COVID-19 vaccines, it could help the U.S. reach its goal of sharing 20 million doses from Johnson & Johnson, Pfizer and Moderna with the rest of the world by the end of June.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.